v3.26.1
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 24, 2025
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Operating activities                
Net income   $ 17,743 $ 26,750 $ 16,638 $ 27,019 $ 44,493 $ 43,657  
Adjustments to reconcile net income to net cash provided by operating activities:                
Stock-based compensation           35,633 27,476  
Gain in fair value of warrant liability   0   0   0 (9,905) $ (9,905)
Amortization of debt discount and issuance costs           595 447  
Depreciation and amortization           1,878 6,545  
Share of net loss of equity method investee   1,109   0   1,109 0  
Provision for expected credit losses           785 69  
Non-cash lease expense           1,459 1,396  
Changes in operating assets and liabilities:                
Accounts receivable           (1,690) (7,555)  
Prepaid expenses and deferred charges           (3,895) (4,103)  
Other current assets           (1,963) 901  
Other assets           (405) (118)  
Accounts payable           1,436 (1,561)  
Accrued expenses and other current liabilities           (4,342) 3,955  
Deferred revenue           633 1,799  
Lease liability           (1,454) (1,523)  
Other liabilities           0 (169)  
Net cash provided by operating activities           74,272 61,311  
Investing activities                
Purchases of property and equipment           (32) (316)  
Loans to equity method investee           (4,000) 0  
Additions to capitalized software development costs           (4,423) (1,192)  
Net cash used in investing activities           (8,455) (1,508)  
Financing activities                
Proceeds from the exercise of stock options           726 1,401  
Principal payments on debt           (10,000) (7,500)  
Payment for the purchase of Equity Instruments           (159,925) 0  
Settlement of Equity Instruments   21,293       32,223 0  
Withholding taxes paid on stock-based compensation           (9,382) (15,430)  
Repurchases of common stock under the stock repurchase program           0 (290,667)  
Proceeds from the exercise of warrants           0 314,124  
Payment for redemption of warrants $ (58)         0 (58)  
Net cash (used in) provided by financing activities           (146,358) 1,870  
Net (decrease) increase in cash, cash equivalents and restricted cash           (80,541) 61,673  
Cash, cash equivalents and restricted cash, beginning of the period $ 59,757   $ 87,650   $ 59,757 87,650 59,757 59,757
Cash, cash equivalents and restricted cash, end of the period   7,109   121,430   7,109 121,430 87,650
Reconciliation of cash, cash equivalents and restricted cash                
Cash and cash equivalents   6,504   120,825   6,504 120,825 87,045
Restricted cash   605   605   605 605  
Cash, cash equivalents and restricted cash   $ 7,109   $ 121,430   7,109 121,430 $ 87,650
Supplemental disclosure of cash flow information:                
Cash interest paid           13,566 7,011  
Income taxes paid           3,834 1,340  
Supplemental disclosure of non-cash investing activities:                
Capitalized software development costs accrued but not paid           143 99  
Supplemental disclosure of non-cash financing activities:                
Issuance of common stock for the settlement of KPI Awards           5,059 3,609  
Withholding taxes on stock-based compensation accrued but not paid           450 66  
Issuance of common stock for the settlement of certain performance stock unit liability-classified awards           0 9,163  
Issuance of common stock for the cashless exercise of warrants           0 63,029  
Issuance of common stock for the exercise of warrants           0 179,186  
Repurchase of common stock committed but not settled           $ 0 $ 3,460